ACE-031 and Oxandrolone Interaction: Monitor | Peptide Database

Rigorous ACE-031 cachexia studies employ a standardised endpoint battery across model systems: Body composition: Longitudinal EchoMRI or DXA scanning from tumour inoculation to study endpoint, recording lean mass, fat mass, and total body water. Lean mass trajectory is the primary efficacy readout. Muscle mass and morphometry: Tibialis anterior, gastrocnemius/soleus complex, and EDL wet weights normalised to tibia length. Cryosection H&E and immunofluorescence for MyHC isoforms with minimal Feret diameter distribution analysis (≥200 fibres per muscle) to distinguish atrophy from developmental hypotrophy. Contractile function: In situ or ex vivo force–frequency curves (10–200 Hz), maximum tetanic force (P0), specific force (P0/CSA), and fatigue index (force retention at 90-second continuous stimulation). Grip strength dynamometry as a non-invasive surrogate. Molecular markers: Western blot for phospho-Smad2/3, phospho-Akt (Ser473), phospho-S6K1 (Thr389), phospho-4E-BP1, MuRF1, atrogin-1, LC3-II/I ratio. RT-qPCR panel: Mstn, Acvr2b, Foxo1, Foxo3a, Mafbx, Trim63, Myod1, Myog, Atg7, Becn1. ELISA for plasma myostatin, activin A, GDF-11, IL-6, TNF-α. Tumour biology: Tumour volume (caliper measurement, twice weekly), tumour weight at necropsy, Ki-67 proliferation index, cleaved caspase-3 apoptosis index, CD31 microvessel density. ACE-031 effects on primary tumour growth are monitored to exclude direct antitumour mechanisms confounding interpretation.

ACE-031 as a research tool is typically produced as a recombinant Fc-fusion protein verified by SDS-PAGE, SEC-HPLC (≥95% monomer), and endotoxin testing (LAL ≤0.1 EU/mg per recombinant protein standards). Ligand binding verification (ELISA or surface plasmon resonance for activin A, myostatin, GDF-11) confirms expected Kd values (~0.1–1 nM for activin A, ~0.5–2 nM for myostatin). For immune assays, Fc region controls (human IgG1 Fc) are mandatory to separate immunological effects of the Fc region (Fcγ receptor binding on macrophages and NK cells) from ligand-capture effects. Assay conditions specifying exogenous ligand concentrations (activin A, myostatin) are essential for reproducibility, as ACE-031’s immune effects in the absence of added ligand depend entirely on endogenous autocrine/paracrine ligand levels which vary substantially between cell types and culture conditions.